Geoffrey Dusheiko
Geoffrey Dusheiko has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Bertoletti
Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore
2 shared publications Chong–Gee Teo
Sexually Transmitted and Blood Borne Virus Laboratory, Public Health Laboratory Service Central Public Health Laboratory, London
1 shared publicationDavid Brown
Department of Hepatology, Royal Free and University College Medical School, London, United Kingdom
1 shared publication- Eleanor Barnes
Oxford University
1 shared publication G Webster
1 shared publicationGeorge J.M. Webster
Department of Hepatology, Royal Free and University College Medical School, London, United Kingdom
1 shared publication
Latest Publications
- 20 October 2004
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 58 (9) , 877-886
Adefovir dipivoxil: review of a novel acyclic nucleoside analogue
Adefovir dipivoxil (ADF) is a novel acyclic nucleoside analogue that has recently been approved for the treatment of chronic hepatitis B virus (HBV). Adefovir was initially assessed at higher doses for the treatment of human immunodeficiency virus (HIV) infection. However, in these studies, nephrotoxicity proved a dose‐limiting side effect. Large randomised controlled studies have recently shown that ADF results in histological, virological and biochemical improvement in both hepatitis B e antigen (HBeAg)‐positive and HBeAg‐negative chronic HBV. While the rate of HBeAg seroconversion at 1 year (12%) was lower than both lamivudine and interferon, this increases with prolonged treatment. The clinical improvements occurred without serious side effects or the development of resistance at the dose of 10 mg daily, in treatment trials of up to 2 years, although resistance has now been observed. In addition, the drug is efficacious in HBV/HIV co‐infection and hepatitis B‐infected liver transplant recipients, particularly in those who have developed lamivudine resistance. ADF can be added as a treatment option to existing treatment options (interferon‐alpha and lamivudine) and assumes a role in the ongoing management of chronic HBV. The optimal use of ADF as either a monotherapy or as part of combination therapy requires further assessment.
- 20 October 2004
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 58 (9) , 877-886
Adefovir dipivoxil: review of a novel acyclic nucleoside analogue
Adefovir dipivoxil (ADF) is a novel acyclic nucleoside analogue that has recently been approved for the treatment of chronic hepatitis B virus (HBV). Adefovir was initially assessed at higher doses for the treatment of human immunodeficiency virus (HIV) infection. However, in these studies, nephrotoxicity proved a dose‐limiting side effect. Large randomised controlled studies have recently shown that ADF results in histological, virological and biochemical improvement in both hepatitis B e antigen (HBeAg)‐positive and HBeAg‐negative chronic HBV. While the rate of HBeAg seroconversion at 1 year (12%) was lower than both lamivudine and interferon, this increases with prolonged treatment. The clinical improvements occurred without serious side effects or the development of resistance at the dose of 10 mg daily, in treatment trials of up to 2 years, although resistance has now been observed. In addition, the drug is efficacious in HBV/HIV co‐infection and hepatitis B‐infected liver transplant recipients, particularly in those who have developed lamivudine resistance. ADF can be added as a treatment option to existing treatment options (interferon‐alpha and lamivudine) and assumes a role in the ongoing management of chronic HBV. The optimal use of ADF as either a monotherapy or as part of combination therapy requires further assessment.
- 1 October 2004
- Published by Elsevier in Gastroenterology
- Vol. 127 (4) , 1131-1138
Evolution of hepatitis B virus during primary infection in humans: Transient generation of cytotoxic T-cell mutants
- 1 October 2004
- Published by Elsevier in Gastroenterology
- Vol. 127 (4) , 1131-1138
Evolution of hepatitis B virus during primary infection in humans: Transient generation of cytotoxic T-cell mutants
- 1 January 2003
- Published by Elsevier in Journal of Hepatology
- Vol. 39, 116-123
Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies
- 1 January 2003
- Published by Elsevier in Journal of Hepatology
- Vol. 39, 116-123
Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies
- Open Access
HCV infection should be managed in specialist centres
Chronic hepatitis C virus (HCV) infection may cause slowly progressive chronic hepatitis, cirrhosis, advanced liver failure, and hepatocellular carcinoma.1 These varying outcomes of type C hepatitis pose a challenge and responsibility which requires firstly, that antiviral treatment is targeted as precisely as possible to those who have progressive disease, and secondly, that patients with advanced disease are managed by specialist centres with the capability of minimising the morbidity of the disease. Presently, most patients with community and hospital associated hepatitis C requiring treatment are referred to specialist liver centres. The hepatologist has a pivotal role in the management of chronic hepatitis C. This includes the differential diagnosis, clinical management, and assessment of the stage of disease. Hepatology has become an increasingly specialised discipline and hepatologists are ideally placed to collate investigations and to ensure the appropriate management of coexisting liver disease. Specialist hepatologists also provide the continuity and follow up required for understanding the sometimes complex dynamic nature of the disease. There is a unique requirement for the histopathological investigation of hepatitis C to inform and deliver the National Institute of Clinical Excellence (NICE) guidelines. Useful classifications for staging and grading of disease have been devised.2 There is a need for experienced clinical input to complement the interpretation of liver biopsies by histopathologists who …
Open AccessHCV infection should be managed in specialist centres
Chronic hepatitis C virus (HCV) infection may cause slowly progressive chronic hepatitis, cirrhosis, advanced liver failure, and hepatocellular carcinoma.1 These varying outcomes of type C hepatitis pose a challenge and responsibility which requires firstly, that antiviral treatment is targeted as precisely as possible to those who have progressive disease, and secondly, that patients with advanced disease are managed by specialist centres with the capability of minimising the morbidity of the disease. Presently, most patients with community and hospital associated hepatitis C requiring treatment are referred to specialist liver centres. The hepatologist has a pivotal role in the management of chronic hepatitis C. This includes the differential diagnosis, clinical management, and assessment of the stage of disease. Hepatology has become an increasingly specialised discipline and hepatologists are ideally placed to collate investigations and to ensure the appropriate management of coexisting liver disease. Specialist hepatologists also provide the continuity and follow up required for understanding the sometimes complex dynamic nature of the disease. There is a unique requirement for the histopathological investigation of hepatitis C to inform and deliver the National Institute of Clinical Excellence (NICE) guidelines. Useful classifications for staging and grading of disease have been devised.2 There is a need for experienced clinical input to complement the interpretation of liver biopsies by histopathologists who …